Paper36449413
Lecanemab in Early Alzheimer's Disease.
van Dyck CH and 18 others. N Engl J Med, 2023. Cited by 4,639 papers, by iCite.
Cite this record
ConductScience Library. Lecanemab in Early Alzheimer's Disease. Papers, record 36449413. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36449413
- Disease
- Alzheimer disease441 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Nootropic Agents | Major topic |
| Humans | |
| Activities of Daily Living | |
| Amyloid beta-Peptides | |
| Cognition | |
| Double-Blind Method |
Source PubMed
Trials10
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05882344 | Cholinergic Deep Brain Stimulation for Alzheimer's Disease | Background | ClinicalTrials.gov | |
| NCT06362707 | Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) | Background | ClinicalTrials.gov | |
| NCT06384573 | DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease | Background | ClinicalTrials.gov | |
| NCT06470061 | RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β | Background | ClinicalTrials.gov | |
| NCT06638632 | Decision Aid for Anti-Amyloid Therapy | Background | ClinicalTrials.gov | |
| NCT06868030 | Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study | Background | ClinicalTrials.gov | |
| NCT07299344 | A Model for Continuous Care of Fragile Patients | Background | ClinicalTrials.gov | |
| NCT07667478 | NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE | Background | ClinicalTrials.gov | |
| NCT07680660 | Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease | Background | ClinicalTrials.gov |
Comments and corrections14
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 36456815 | Heralded Alzheimer's drug works - but safety concerns loom. | https://conductscience.org/library/papers/36456815 | PubMed |
| Comment in | 36599061 | Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. | https://conductscience.org/library/papers/36599061 | PubMed |
| Comment in | 36599066 | Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody. | https://conductscience.org/library/papers/36599066 | PubMed |
| Comment in | 36599073 | Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. | https://conductscience.org/library/papers/36599073 | PubMed |
| Comment in | 36609712 | Lecanemab trial in AD brings hope but requires greater clarity. | https://conductscience.org/library/papers/36609712 | PubMed |
| Comment in | 36627422 | FDA approves Alzheimer's drug lecanemab amid safety concerns. | https://conductscience.org/library/papers/36627422 | PubMed |
| Comment in | 36781970 | Drug trial for Alzheimer's disease is a game changer. | https://conductscience.org/library/papers/36781970 | PubMed |
| Comment in | 36869178 | FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. | https://conductscience.org/library/papers/36869178 | PubMed |
| Comment in | 37081342 | Neuer Antikörper bremst kognitiven Verfall. | https://conductscience.org/library/papers/37081342 | PubMed |
| Comment in | 37099351 | Lecanemab in Early Alzheimer's Disease. | https://conductscience.org/library/papers/37099351 | PubMed |
| Comment in | 37099352 | Lecanemab in Early Alzheimer's Disease. | https://conductscience.org/library/papers/37099352 | PubMed |
| Comment in | 37099353 | Lecanemab in Early Alzheimer's Disease. | https://conductscience.org/library/papers/37099353 | PubMed |
| Comment in | 37099354 | Lecanemab in Early Alzheimer's Disease. | https://conductscience.org/library/papers/37099354 | PubMed |
| Comment in | 37099355 | Lecanemab in Early Alzheimer's Disease. Reply. | https://conductscience.org/library/papers/37099355 | PubMed |
Cited by3,459
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,639 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42988979 | Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease. | Neurol Sci | 2026 | https://conductscience.org/library/papers/42988979 | PubMed |
| 42985795 | Deep Learning for AD Risk Screening and Progression Prediction. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42985795 | PubMed |
| 42985466 | Alzheimer's Disease: Mechanisms and Therapeutic Advances. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42985466 | PubMed |
| 42984124 | Intrathecal Transplantation of Human Umbilical Cord-Derived MSCs Outperforms Intravenous Administration in Attenuating Pathology and Cognitive Deficits in Alzheimer's Disease Mice. | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/42984124 | PubMed |
| 42982982 | Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan. | J Hum Genet | 2026 | https://conductscience.org/library/papers/42982982 | PubMed |
| 42982811 | Physiological APP processing is required for synaptic plasticity and cognition. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42982811 | PubMed |
| 42980730 | From molecular pathways to nanocarrier design: a translational framework for lipid-based nanoparticles in Alzheimer's disease. | Discov Nano | 2026 | https://conductscience.org/library/papers/42980730 | PubMed |
| 42978683 | Integrated computational screening and biochemical validation identify natural small molecules targeting Aβ aggregation and dissociation. | J Pharm Pharm Sci | 2026 | https://conductscience.org/library/papers/42978683 | PubMed |
| 42969459 | Navigating the Challenges of Shared Decision-Making in Amyloid Immunotherapy for Alzheimer's Disease. | Eur J Neurol | 2026 | https://conductscience.org/library/papers/42969459 | PubMed |
| 42968820 | Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026. | Clin Interv Aging | 2026 | https://conductscience.org/library/papers/42968820 | PubMed |
| 42967498 | Measuring mild cognitive impairment using routinely collected health-care data: A conceptual framework and guidance for embedded pragmatic clinical trials. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42967498 | PubMed |
| 42963333 | Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42963333 | PubMed |
| 42961631 | Cost-Effectiveness Analysis of Disease-Modifying Therapies for Early Alzheimer's Disease in China. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42961631 | PubMed |
| 42960521 | The Association of Amyloid-β and Tau With Synaptic Dysfunction in Alzheimer's Disease. | Ann Clin Transl Neurol | 2026 | https://conductscience.org/library/papers/42960521 | PubMed |
| 42959393 | Differences in anti-amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42959393 | PubMed |
| 42957970 | APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42957970 | PubMed |
| 42953588 | TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42953588 | PubMed |
| 42952982 | Peripheral serum copper metabolite levels measured by ultrafiltration aid in the clinical screening of Alzheimer's disease. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42952982 | PubMed |
| 42951866 | Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta-Analysis. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42951866 | PubMed |
| 42948157 | Heterogeneous progression of AT(N) biomarkers in data-driven subtypes of Alzheimer's disease. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42948157 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| LECANEMAB | CHEMBL3833321 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3833321 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36449413
GET https://conductscience.org/api/papers/v1/36449413/cited_by?page=2